Literature DB >> 24876718

Occult hepatitis B virus and hepatocellular carcinoma.

Teresa Pollicino1, Carlo Saitta1.   

Abstract

Occult hepatitis B virus (HBV) infection (OBI) is a challenging pathobiological and clinical issue that has been widely debated for several decades. By definition, OBI is characterized by the persistence of HBV DNA in the liver tissue (and in some cases also in the serum) in the absence of circulating HBV surface antigen (HBsAg). Many epidemiological and molecular studies have indicated that OBI is an important risk factor for hepatocellular carcinoma (HCC) development. OBI may exert direct pro-oncogenic effects through the activation of the same oncogenic mechanisms that are activated in the course of an HBsAg-positive infection. Indeed, in OBI as in HBV-positive infection, HBV DNA can persist in the hepatocytes both integrated into the host genome as well as free episome, and may maintain the capacity to produce proteins-mainly X protein and truncated preS-S protein - provided with potential transforming properties. Furthermore, OBI may indirectly favor HCC development. It has been shown that the persistence of very low viral replicative activity during OBI may induce mild liver necro-inflammation continuing for life, and substantial clinical evidence indicates that OBI can accelerate the progression of liver disease towards cirrhosis that is considered the most important risk factor for HCC development.

Entities:  

Keywords:  HBx protein; Hepatitis B virus; Hepatitis B virus DNA; Hepatitis B virus surface antigen; Hepatocellular carcinoma; Occult hepatitis B virus infection

Mesh:

Substances:

Year:  2014        PMID: 24876718      PMCID: PMC4033435          DOI: 10.3748/wjg.v20.i20.5951

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  112 in total

Review 1.  Diverse roles of hepatitis B virus in liver cancer.

Authors:  Guillaume Fallot; Christine Neuveut; Marie-Annick Buendia
Journal:  Curr Opin Virol       Date:  2012-06-19       Impact factor: 7.090

Review 2.  Hepatitis B virus biology.

Authors:  C Seeger; W S Mason
Journal:  Microbiol Mol Biol Rev       Date:  2000-03       Impact factor: 11.056

3.  What is the clinical impact of occult hepatitis B virus infection?

Authors:  Giovanni Raimondo; Teresa Pollicino; Giovanni Squadrito
Journal:  Lancet       Date:  2005 Feb 19-25       Impact factor: 79.321

4.  Hepatitis B vaccination and reduced risk of primary liver cancer among male adults: a cohort study in Korea.

Authors:  M S Lee; D H Kim; H Kim; H S Lee; C Y Kim; T S Park; K Y Yoo; B J Park; Y O Ahn
Journal:  Int J Epidemiol       Date:  1998-04       Impact factor: 7.196

5.  Identification of human cancer-related genes by naturally occurring Hepatitis B Virus DNA tagging.

Authors:  D Gozuacik; Y Murakami; K Saigo; M Chami; C Mugnier; D Lagorce; T Okanoue; T Urashima; C Bréchot; P Paterlini-Bréchot
Journal:  Oncogene       Date:  2001-09-27       Impact factor: 9.867

6.  Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study.

Authors:  Kazuki Ikeda; Hiroyuki Marusawa; Yukio Osaki; Takefumi Nakamura; Naoto Kitajima; Yukitaka Yamashita; Masatoshi Kudo; Tosiya Sato; Tsutomu Chiba
Journal:  Ann Intern Med       Date:  2007-05-01       Impact factor: 25.391

Review 7.  Persistent occult hepatitis B virus infection: experimental findings and clinical implications.

Authors:  Patricia M Mulrooney-Cousins; Tomasz I Michalak
Journal:  World J Gastroenterol       Date:  2007-11-21       Impact factor: 5.742

8.  Influence of occult hepatitis B virus coinfection on the incidence of fibrosis and hepatocellular carcinoma in chronic hepatitis C.

Authors:  Shunichi Matsuoka; Kazushige Nirei; Akinori Tamura; Hitomi Nakamura; Hiroshi Matsumura; Shuu Oshiro; Yasuo Arakawa; Hiroaki Yamagami; Naohide Tanaka; Mitsuhiko Moriyama
Journal:  Intervirology       Date:  2009-01-07       Impact factor: 1.763

9.  Pathological characteristics of patients who develop hepatocellular carcinoma with negative results of both serous hepatitis B surface antigen and hepatitis C virus antibody.

Authors:  Reiichiro Kondo; Osamu Nakashima; Michio Sata; Fumio Imazeki; Osamu Yokosuka; Ken Tanikawa; Masayoshi Kage; Hirohisa Yano
Journal:  Hepatol Res       Date:  2013-09-17       Impact factor: 4.288

10.  State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases.

Authors:  C Bréchot; M Hadchouel; J Scotto; M Fonck; F Potet; G N Vyas; P Tiollais
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

View more
  18 in total

Review 1.  Natural regression of fibrosis in chronic hepatitis B.

Authors:  Shogo Ohkoshi; Haruka Hirono; Kazuhiko Watanabe; Katsuhiko Hasegawa; Kenya Kamimura; Masahiko Yano
Journal:  World J Gastroenterol       Date:  2016-06-28       Impact factor: 5.742

2.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George
Journal:  Hepatol Int       Date:  2020-10-01       Impact factor: 6.047

3.  Hepatocellular carcinoma: Clinical-pathological features and HIV infection in Mozambican patients<sup/>.

Authors:  Lina Cunha; Carla Carrilho; Nilesh Bhatt; Michella Loforte; Cremildo Maueia; Fabíola Fernandes; Assucena Guisseve; Francisco Mbofana; Fatima Maibaze; Liana Mondlane; Muhammad Ismail; Luzmira Dimande; Sheila Machatine; Nuno Lunet; Yu-Tsueng Liu; Eduardo Samo Gudo; Pascal Pineau
Journal:  Cancer Treat Res Commun       Date:  2019-03-16

Review 4.  What Comes First: Treatment of Viral Hepatitis or Liver Cancer?

Authors:  Jordan J Feld; Lisette A P Krassenburg
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

Review 5.  Current hepatitis B virus infection situation in Indonesia and its genetic diversity.

Authors:  Maria Inge Lusida; Yoshihiko Yano
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

6.  Risk factors for non-alcoholic fatty liver disease are common in patients with non-B non-C hepatocellular carcinoma in India.

Authors:  Deepu David; Anantharam Raghavendran; Ashish Goel; C Bharath Kumar; Thomas Alex Kodiatte; Deepak Burad; Priya Abraham; Banumathi Ramakrishna; Philip Joseph; Jeyamani Ramachandran; C E Eapen
Journal:  Indian J Gastroenterol       Date:  2017-10-04

7.  Occult HBV infection status and its impact on surgical outcomes in patients with curative resection for HCV-associated hepatocellular carcinoma.

Authors:  Koutaro Yamaji; Keita Kai; Sho Komukai; Hiroki Koga; Takao Ide; Atsushi Kawaguchi; Hirokazu Noshiro; Shinichi Aishima
Journal:  Hepatobiliary Surg Nutr       Date:  2018-12       Impact factor: 7.293

8.  Hepatitis B virus replication and sex-determining region Y box 4 production are tightly controlled by a novel positive feedback mechanism.

Authors:  Jian Shang; Yuan Zheng; Xiaohong Guo; Jiayin Mo; Xueping Xie; Ying Xiong; Yingle Liu; Kailang Wu; Jianguo Wu
Journal:  Sci Rep       Date:  2015-05-13       Impact factor: 4.379

9.  Spontaneous HBsAg loss in Korean patients: relevance of viral genotypes, S gene mutations, and covalently closed circular DNA copy numbers.

Authors:  Kyun-Hwan Kim; Hye-Young Chang; Jun Yong Park; Eun-Sook Park; Yong Kwang Park; Kwang-Hyub Han; Sang Hoon Ahn
Journal:  Clin Mol Hepatol       Date:  2014-09-25

10.  Characterization of Novel Hepatitis B Virus PreS/S-Gene Mutations in a Patient with Occult Hepatitis B Virus Infection.

Authors:  Jianhong Chen; Yan Liu; Jun Zhao; Zhihui Xu; Rongjuan Chen; Lanlan Si; Shanshan Lu; Xiaodong Li; Shuai Wang; Kai Zhang; Jin Li; Juqiang Han; Dongping Xu
Journal:  PLoS One       Date:  2016-05-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.